Ista Istalol Intent: Outsample, Outpromote Other Ophthalmic Beta Blockers
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Ista plans to outsample competing products in an effort to make Istalol the leading agent in the $170 mil. ophthalmic beta blocker market.
You may also be interested in...
Ista Vitrase Launch Set For Early 2005 With Approval Of Smaller Vial Size
Vitrase launch set for early 2005 with approval of smaller vial size. Ista plans to differentiate the spreading agent based on preservative-free formulation and 200 unit/mL vial size. The company remains in discussions with FDA about “approvable” letter for vitreous hemorrhage indication
Ista Vitrase Launch Set For Early 2005 With Approval Of Smaller Vial Size
Vitrase launch set for early 2005 with approval of smaller vial size. Ista plans to differentiate the spreading agent based on preservative-free formulation and 200 unit/mL vial size. The company remains in discussions with FDA about “approvable” letter for vitreous hemorrhage indication
Ista Vitrase Could Get Restricted Vitreous Hemorrhage Indication, Firm Says
Approval of Ista’s Vitrase in vitreous hemorrhage would likely be restricted to patients with diabetic retinopathy as an underlying cause, Ista suggested.